---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028563"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:31:33.468642+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology shifts lead program to first-line RAS-mutated mCRC; Q2 cash burn $7.1M, runway into 2025

## Summary
- New lead program in first-line RAS-mutated mCRC; interim topline data expected mid-2024; FDA agreed on endpoints for accelerated approval.
- Cash $89.4M as of June 30, 2023; net cash used in operations $7.1M in Q2; runway into 2025.
- Expanded Pfizer relationship: Pfizer Ignite to handle clinical execution of CRDF-004 Phase 2 trial.
- Operating expenses $12.3M for Q2 2023, up from $10.5M in Q2 2022 due to higher headcount and stock-based compensation.
- Upcoming milestones: mPDAC data Q3'23, SCLC data Q3'23, TNBC data Q4'23/Q1'24.

## SEC filing metadata
- accession: 0001628280-23-028563
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/0001628280-23-028563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/crdf-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028563
- JSON: https://secwatch.observer/filing/0001628280-23-028563.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028563.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 9, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/0001628280-23-028563-index.htm
- Governance Changes
  Cardiff Oncology, Inc.: Filed Certificate of Elimination to remove designations of Series B, C, D, and E Convertible Preferred Stock, returning those shares to authorized but unissued preferred stock (effective 2023-08-08).
  - Change: charter amendment
  - Effective: 2023-08-08
  source text: On August 8, 2023, Cardiff Oncology, Inc. (the “Company”) filed, with the Secretary of State of the State of Delaware, a Certificate of Elimination (the “Certificate of Elimination”) of Series B, Series C, Series D and Series E Convertible Preferred Stock removing the designation and other references to its Series B, Series C, Series D and Series E Convertible Stock from the Company’s Amended and Restated Certificate of Incorporation, as amended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/0001628280-23-028563-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.